BioHarvest Sciences Inc

BioHarvest Sciences Inc(BHST)股票分析

$1.580

+0.095 (+6.04%)收盤時

Loading chart…
最高
1.660
開盤
1.510
成交量加權均價
1.57
成交量
55.74K
市值
—
最低
1.460
成交金額
87.32K
企業價值/稅息折舊攤銷前利潤(TTM)
-2.85

BioHarvest Sciences Inc. is a Canada-based botanical synthesis company. The Company leverages its technology platform to grow plant-based compounds, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop science-based therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking plant-based compounds, and as a creator of nutraceutical health and wellness products, which include dietary supplements. It delivers phytochemicals such as age-defying antioxidants and polyphenols used for wellness. Its product pipeline is focused on polyphenols, which include grape cells, olive cells, and pomegranate cells. Its process involves selecting the specific plant cells that can create the targeted ingredients. It offers VINIA, which is a nutraceutical containing the entire matrix of polyphenols contained in red grapes, including Piceid resveratrol.

AI 分析 of BioHarvest Sciences Inc (BHST)

持有

Bioharvest Sciences Inc (BHST) is currently not a strong buy due to its low RSI of 32.086, indicating oversold conditions, and a significant year-to-date change of -69.87%. However, the company has shown revenue growth of 8% year-over-year in Q1 2026, with a projected annual revenue guidance of $42 million to $48 million, suggesting potential for recovery. The main risk is the forward P/E of 153.846, indicating high valuation expectations despite ongoing losses.

估值指標

BioHarvest Sciences Inc(BHST)目前預期本益比為 153.85,5 年平均預期本益比為 66.35。

預期本益比

合理
5 年均值 P/E
66.35
目前P/E
153.85
高估
162.88
低估
-30.18

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
167.45
目前EV/EBITDA
-2.85
高估
801.58
低估
-466.68

預期股價營收比

低估
5 年均值 P/S
2.31
目前P/S
0.68
高估
3.47
低估
1.14

BHST 常見問題 —— 由 Alphio AI 解答

BioHarvest Sciences Inc. is a Canada-based botanical synthesis company. The Company leverages its technology platform to grow plant-based compounds, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop science-based therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking plant-based compounds, and as a creator of nutraceutical health and wellness products, which include dietary supplements. It delivers phytochemicals such as age-defying antioxidants and polyphenols used for wellness. Its product pipeline is focused on polyphenols, which include grape cells, olive cells, and pomegranate cells. Its process involves selecting the specific plant cells that can create the targeted ingredients. It offers VINIA, which is a nutraceutical containing the entire matrix of polyphenols contained in red grapes, including Piceid resveratrol. It operates in the Healthcare sector.

Bioharvest Sciences Inc (BHST) is currently not a strong buy due to its low RSI of 32.086, indicating oversold conditions, and a significant year-to-date change of -69.87%. However, the company has shown revenue growth of 8% year-over-year in Q1 2026, with a projected annual revenue guidance of $42 million to $48 million, suggesting potential for recovery. The main risk is the forward P/E of 153.846, indicating high valuation expectations despite ongoing losses.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易